An obesity drug deep-dive, and peptides move mainstream - Scorecard - MDSpire

An obesity drug deep-dive, and peptides move mainstream

  • By

  • Allison DeAngelis

  • Elaine Chen

  • Adam Feuerstein

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Exploring Advances in Obesity Treatments: The Rise of Peptides in Mainstream Medicine

At a Glance

CategoryDetail
Condition
Key MechanismsPeptides such as GLP-1; note BPC-157 is not FDA-approved for obesity.
Target Population
Care Setting

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

  • Consider BMI and comorbidities for obesity diagnosis.

Management

  • Implement lifestyle changes alongside medication.

Monitoring & Follow-up

  • Regular follow-ups to assess weight loss and side effects.

Risks

  • Monitor for potential side effects of GLP-1 and other peptides.

Patient & Prescribing Data

Individuals with obesity seeking treatment options

Emerging medications including GLP-1 and other peptides

Clinical Best Practices

  • add

Related Resources & Content

Original Source(s)

An obesity drug deep-dive, and peptides move mainstream

  • by Allison DeAngelis, Elaine Chen, Adam Feuerstein

  • June 11, 2026

Related Content

Identification and management of unrecognized femoral head epiphysiolysis: a case report

Error in Open Access Status

  • June 1, 2026

Side Effects: Context Is the Diagnosis

This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.